A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer

Prior treatment

• Subjects are known to have genetic abnormalities with approved targeted drug therapy.
• Subjects with severe active infection within 4 weeks prior to initiation of study treatment; Or unexplained fever \>38.0 ℃ occurred during screening and before first administration;
• Patients with active tuberculosis within 1 year prior to enrollment;
• Preparing for or having previously received an organ transplant, or having received a hematopoietic stem cell transplant within 60 days prior to initial medication, or having a significant host transplant response;
• Patients who required immunosuppressive, systemic, or absorbable topical hormone therapy for immunosuppressive purposes and continued use within two weeks prior to randomization
• Severe infection of grade 4 or higher occurred within 1 year prior to initiation of study therapy;
• Participated in clinical trials of other drugs within 30 days;
• History of live attenuated vaccine vaccination within 28 days prior to randomization or planned live attenuated vaccine vaccination during the study period;
• Received Chinese patent drugs with anti-tumor indications specified in the National Medical Product Administration approved drug package inserts within 2 weeks prior to initiation of administration
• Had major surgery within 4 weeks prior to initiation of medication;

Other illness

• Present or complication with other malignancies within 5 years.
• Cirrhosis, active hepatitis;
• Immunodeficiency disease;
• History of active autoimmune disease or autoimmune disease;
• Severe lung disease;
• History of pituitary or adrenal dysfunction;
• History of severe mental disorder;
• History of drug abuse, alcoholism or drug use;

Lab values

• Other severe, acute, or chronic medical conditions or laboratory abnormalities that, in the investigator's opinion, may increase the risks associated with study participation or may interfere with the interpretation of the study results, or are otherwise unsuitable for participation in the clinical study;

Other

• Cardio-cerebrovascular abnormalities;
• The compliance of patients to participate in this clinical study is estimated to be insufficient.

• patients with stage II-IIIB (T3N2M0 only) Non-Small Cell Lung Carcinoma (NSCLC) and determined to be eligible for curable R0 excision, after pathologic diagnosis of puncture specimens;
• ≥18 years old (calculated on the date of signing the informed consent); Both men and women; Eastern Cooperative Oncology Group (ECOG) score 0\~1; Predicted survival ≥3 months;
• Have at least 1 measurable lesion according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 criteria within 28 days prior to initiation of treatment;
• Has not received systemic antitumor therapy, including radiotherapy, chemotherapy and immunotherapy;
• Agree to provide fresh or 6 month tumor tissue for programmed death ligand -1 (PD-L1) testing.
• Major organs are functioning well.
• Women of reproductive age should agree that they must use effective birth control during the study period and for 6 months after the study, and that a negative serum or urine pregnancy test occurred within 7 days prior to study enrollment; Men should agree that effective contraception must be used during the study period and for 6 months after the study period ends.
• The subjects voluntarily joined the study and signed the informed consent with good compliance.